Our Research Publications
Updated November 2023
Pagination
- Previous page
- Page 29
- Next page
Title | Authors | Year | Journal | Link to Article | Intended Audience Sort descending | Purpose |
---|---|---|---|---|---|---|
Bleeding complications in immune thrombocytopenia | Arnold DM | 2015 | Hematology Am Soc Hematol Educ Program | View Bleeding complications in immune thrombocytopenia | Health care providers | Clinical research |
CMV seronegative, irradiated and washed blood components | Prokopchuk-Gauk O, Solh Z | 2017 | Clinical Guide to Transfusion | View CMV seronegative, irradiated and washed blood components | Health care providers | Benchmarking and standard setting |
Counting platelets at transfusion threshold levels: impact on the decision to transfuse. A BEST Collaborative - UK NEQAS(H) International Exercise | Lozano M, Mahon A, van der Meer PF, Stanworth S, Cid J, Devine D, Fung MK, de la Salle B, Heddle NM, on behalf of Biomedical Excellence for Safer Transfusion Collaborative | 2014 | Vox Sang | View Counting platelets at transfusion threshold levels: impact on the decision to transfuse. A BEST Collaborative - UK NEQAS(H) International Exercise | Health care providers | Benchmarking and standard setting |
Expert approaches to common bleeding and thrombotic problems-part I | Hayward CP, Webert KE | 2012 | Semin Thromb Hemost | View Expert approaches to common bleeding and thrombotic problems-part I | Health care providers | Other |
Modeling of body weight metrics for effective and cost-efficient conventional factor VIII dosing in hemophilia A prophylaxis | McEneny-King A, Chelle P, Henrard S, Hermans C, Iorio A, Edginton AN | 2017 | Pharmaceutics | View Modeling of body weight metrics for effective and cost-efficient conventional factor VIII dosing in hemophilia A prophylaxis | Health care providers | Clinical research |
Peanut and fish allergy due to platelet transfusion in a child | Ching JC, Lau W, Hannach B, Upton JE | 2015 | CMAJ | View Peanut and fish allergy due to platelet transfusion in a child | Health care providers | Clinical research |
Platelet product quality remains high after seven days of storage | Serrano K, Schubert P, Devine D | 2017 | Blood.ca website | View Platelet product quality remains high after seven days of storage | Health care providers | New or improved product or process |
Pre-transfusion testing | Lane D | 2017 | Clinical Guide to Transfusion | View Pre-transfusion testing | Health care providers | Benchmarking and standard setting |
Questioning some recommendations in the umbilical cord blood guideline | Elmoazzen H, Petraszko T | 2018 | J Obstet Gynaecol Can | View Questioning some recommendations in the umbilical cord blood guideline | Health care providers | New or improved product or process |
Residual Risk of HIV, HCV and HBV in Canada | O'Brien SF, Yi Q-L, Fan W, Scalia V, Goldman M, Fearon MA | 2017 | Transfus Apher Sci | View Residual Risk of HIV, HCV and HBV in Canada | Health care providers | Clinical research |
The cost of transfusing a unit of red blood cells: a costing model for Canadian hospital use | Lagerquist O, Poseluzny D, Werstiuk G, Slomp J, Maier M, Nahirniak S, Clarke G | 2017 | ISBT Sci Ser | View The cost of transfusing a unit of red blood cells: a costing model for Canadian hospital use | Health care providers | Ethical, legal and social implications research |
Circular of information for the use of human blood components: Platelets | Jenkins C | 2018 | Blood.ca website | View Circular of information for the use of human blood components: Platelets | Health care providers | Benchmarking and standard setting |
Aphérèse thérapeutique | Pavenski K | 2018 | Guide de la pratique transfusionnelle | View Aphérèse thérapeutique | Health care providers | Benchmarking and standard setting |
Plerixafor effectively mobilizes CD56bright NK cells in blood, providing an allograft predicted to protect against GVHD | Wong PPC, Kariminia A, Jones D, Eaves CJ, Foley R, Ivison S, Couban S, Schultz KR | 2018 | Blood | View Plerixafor effectively mobilizes CD56bright NK cells in blood, providing an allograft predicted to protect against GVHD | Health care providers | Clinical research |
Circular of information for the use of human blood components: Plasma Components | Jenkins C | 2019 | Blood.ca website | View Circular of information for the use of human blood components: Plasma Components | Health care providers | Benchmarking and standard setting |
Kell System: Anti-Jsa | Meunier D, Peng S, Clarke G | 2019 | Blood.ca website | View Kell System: Anti-Jsa | Health care providers | Benchmarking and standard setting |
Pour un bon équilibre : protection des données dan les travaux de recherche | Ward R | 2019 | Blood.ca website | View Pour un bon équilibre : protection des données dan les travaux de recherche | Health care providers | Other |
Système Lutheran : l’anticorps anti-Lua | Meunier D, Peng S, Clarke G | 2019 | Blood.ca website | View Système Lutheran : l’anticorps anti-Lua | Health care providers | Benchmarking and standard setting |
Circular of information for the use of human blood components: Plasma components | Jenkins C | 2021 | Blood.ca website | Health care providers | Benchmarking and standard setting | |
A decision integration strategy for short-term demand forecasting and ordering for red blood cell components | Li N, Chiang F, Down DG, Heddle NM | 2021 | Oper Res Health Care | View A decision integration strategy for short-term demand forecasting and ordering for red blood cell components | Health care providers | New or improved product or process |
Chapitre 6: Sélection des donneurs, dépistage des maladies transmissibles et réduction des agents pathogènes | Drews S, Khandelwal A, Goldman M, Devine D | 2021 | Guide de la pratique transfusionnelle | View Chapitre 6: Sélection des donneurs, dépistage des maladies transmissibles et réduction des agents pathogènes | Health care providers | Benchmarking and standard setting |
FAQ: Donor high titre isohemagglutinin (anti-A/anti-B) testing at Canadian Blood Services | Bodnar M, Bienz M, Clarke G | 2022 | Blood.ca website | View FAQ: Donor high titre isohemagglutinin (anti-A/anti-B) testing at Canadian Blood Services | Health care providers | New or improved product or process |
Prophylaxis use of clotting factor replacement products in people with non-severe haemophilia: A review of the literature | Iorio A, Königs C, Reding MT, Rotellini D, Skinner MW, Mancuso ME, Berntorp E | 2023 | Haemophilia | View Prophylaxis use of clotting factor replacement products in people with non-severe haemophilia: A review of the literature | Health care providers | Clinical research |
International guidelines regarding the role of IVIG in the management of Rh- and ABO-mediated haemolytic disease of the newborn | Lieberman L, Lopriore E, Baker JM, Bercovitz RS, Christensen RD, Crighton G, Delaney M, Goel R, Hendrickson JE, Keir A, Landry D, La Rocca U, Lemyre B, Maier RF, Muniz-Diaz E, Nahirniak S, New HV, Pavenski K, Dos Santos MCP, Ramsey G, Shehata N, International Collaboration for Transfusion Medicine Guidelines | 2022 | Brit J Haem | View International guidelines regarding the role of IVIG in the management of Rh- and ABO-mediated haemolytic disease of the newborn | Health care providers | Benchmarking and standard setting |
A prospective study measuring the development of antibodies against platelet factor 4-heparin in healthy males after exposure to heparins | Kelton JG, Warkentin TE, Moore JC, Arnold DM, Nazi I, Arepally GM, Roach JM, Fier I | 2012 | J Thromb Haemost | View A prospective study measuring the development of antibodies against platelet factor 4-heparin in healthy males after exposure to heparins | Health care providers | Clinical research |
Autoimmune heparin-induced thrombocytopenia | Greinacher A, Selleng K, Warkentin TE | 2017 | J Thromb Haemost | View Autoimmune heparin-induced thrombocytopenia | Health care providers | Clinical research |
Changes in coagulation factor activity and content of di(2-ethylhexyl)phthalate in frozen plasma units during refrigerated storage for up to five days after thawing | Sheffield WP, Bhakta V, Mastronardi C, Ramirez-Arcos S, Howe D, Jenkins C | 2012 | Transfusion | View Changes in coagulation factor activity and content of di(2-ethylhexyl)phthalate in frozen plasma units during refrigerated storage for up to five days after thawing | Health care providers | New or improved product or process |
How we treat thrombotic thrombocytopenic purpura: Results of a Canadian TTP practice survey | Patriquin CJ, Clark WF, Pavenski K, Arnold DM, Rock G, Foley SR, for the Canadian Apheresis Group | 2016 | J Clin Apher | View How we treat thrombotic thrombocytopenic purpura: Results of a Canadian TTP practice survey | Health care providers | Clinical research |
Impact of Pandemic Influenza A (H1N1) on Laboratory Services | Patel SN, Gubbay JB, Bastien N, Booth T, Charest H, Chernesky M, Couillard M, Drews S, Garceau R, Gubbay J, Guercio S, Fearon M, Fonseca K, Hatchette T, Horsman G, Larke B, Li Y, Majury A, Ouellette O, Petric M, Ratnam S, Sevenhuysen C, Van Caeseele P | 2012 | National Collaborating Centre for Infectious Diseases: Evidence Reviews on Pandemic H1N1 | View Impact of Pandemic Influenza A (H1N1) on Laboratory Services | Health care providers | Other |
Les composants sanguins | Clarke G | 2017 | Guide de la pratique transfusionnelle | View Les composants sanguins | Health care providers | Benchmarking and standard setting |
Mortality outcomes in patients transfused with fresher versus older red blood cells: a meta-analysis | Chai-Adisaksopha C, Alexander PE, Guyatt G, Crowther MA, Heddle NM, Devereaux PJ, Ellis M, Roxby D, Sessler DI, Eikelboom JW | 2017 | Vox Sang | View Mortality outcomes in patients transfused with fresher versus older red blood cells: a meta-analysis | Health care providers | Clinical research |
Optimal transfusion practices after allogeneic hematopoietic cell transplantation: a systematic scoping review of evidence from randomized controlled trials | Christou G, Iyengar A, Shorr R, Tinmouth A, Saidenberg E, Maze D, Tay J, Bredeson C, Allan DS | 2016 | Transfusion | View Optimal transfusion practices after allogeneic hematopoietic cell transplantation: a systematic scoping review of evidence from randomized controlled trials | Health care providers | Clinical research |
Sialidase inhibition to increase platelet counts: A new treatment option for thrombocytopenia | Jansen AJG, Peng J, Zhao H-G, Hou M, Ni H | 2015 | Am J Hematol | View Sialidase inhibition to increase platelet counts: A new treatment option for thrombocytopenia | Health care providers | Clinical research |
Sustained remissions of immune thrombocytopenia associated with the use of thrombopoietin receptor agonists | Ghadaki B, Nazi I, Kelton JG, Arnold DM | 2013 | Transfusion | View Sustained remissions of immune thrombocytopenia associated with the use of thrombopoietin receptor agonists | Health care providers | Clinical research |
What should men living with severe haemophilia need to know? The perspectives of Canadian haemophilia health care providers | Lane S, Arnold E, Webert KE, Chan A, Walker I, Heddle NM | 2013 | Haemophilia | View What should men living with severe haemophilia need to know? The perspectives of Canadian haemophilia health care providers | Health care providers | Other |
How do we diagnose immune thrombocytopenia in 2018? | Kelton JG VJ, Arnold DM | 2018 | Hematology Am Soc Hematol Educ Program | View How do we diagnose immune thrombocytopenia in 2018? | Health care providers | Clinical research |
Past, present and future of haemophilia gene therapy: From vectors and transgenes to known and unknown outcomes | Pierce GF, Iorio A | 2018 | Haemophilia | View Past, present and future of haemophilia gene therapy: From vectors and transgenes to known and unknown outcomes | Health care providers | New or improved product or process |
Concurrence of symmetrical peripheral gangrene and venous limb gangrene following polytrauma: a case report | Tan JH, Mohamad Y, Tan CLH, Kassim M, Warkentin TE | 2018 | J Med Case Rep | View Concurrence of symmetrical peripheral gangrene and venous limb gangrene following polytrauma: a case report | Health care providers | Clinical research |
Correction to: Routine clinical care data for population pharmacokinetic modeling: the case for Fanhdi/Alphanate in hemophilia A patients | Chelle P, Yeung CHT, Bonanad S, Morales Munoz JC, Ozelo MC, Megias Vericat JE, Iorio A, Spears J, Mir R, Edginton A | 2019 | J Pharmacokinet Pharmacodyn | View Correction to: Routine clinical care data for population pharmacokinetic modeling: the case for Fanhdi/Alphanate in hemophilia A patients | Health care providers | Clinical research |
Guidelines on the intraoperative transfusion of red blood cells: a protocol for systematic review | Baker L, Park L, Gilbert R, Martel A, Ahn H, Davies A, McIsaac DI, Saidenberg E, Tinmouth A, Fergusson DA, Martel G | 2019 | BMJ Open | View Guidelines on the intraoperative transfusion of red blood cells: a protocol for systematic review | Health care providers | Clinical research |
ResearchUnit: Reducing bleeding after cardiac surgery: fibrinogen concentrate vs cryoprecipitate | Karkouti K | 2020 | Blood.ca website | View ResearchUnit: Reducing bleeding after cardiac surgery: fibrinogen concentrate vs cryoprecipitate | Health care providers | Clinical research |
Comparison of short-term mortality between mechanically ventilated patients with COVID-19 and influenza in a setting of sustainable healthcare system | Lee J, Lee YH, Chang H-H, Choi SH, Seo H, Yoo SS, Lee SY, Cha SI, Park JY, Kim CH | 2020 | J Infect | View Comparison of short-term mortality between mechanically ventilated patients with COVID-19 and influenza in a setting of sustainable healthcare system | Health care providers | Clinical research |
Dupilumab, severe asthma airway responses, and SARS-CoV-2 serology | Bhalla A, Mukherjee M, Radford K, Nazy I, Kjarsgaard M, Bowdish DME, Nair P | 2021 | Allergy | View Dupilumab, severe asthma airway responses, and SARS-CoV-2 serology | Health care providers | Basic research |
High-dose IVIG plus cangrelor platelet "anesthesia" during urgent heparin-CPB in a patient with recent SRA-negative HIT-thrombosis with persisting platelet-activating antibodies | Koster A, Nazy I, Birschmann IE, Smith JW, Sheppard JI, Warkentin TE | 2020 | Res Pract Thromb Haemost | View High-dose IVIG plus cangrelor platelet "anesthesia" during urgent heparin-CPB in a patient with recent SRA-negative HIT-thrombosis with persisting platelet-activating antibodies | Health care providers | Clinical research |
Adverse reactions reporting | Yan M | 2021 | Blood.ca website | View Adverse reactions reporting | Health care providers | Benchmarking and standard setting |
What constitutes the most cautious approach for a pregnant person with weak D type 4.0? | Lieberman L, Flegel W, Bodnar M, Clarke G, Hannon J | 2021 | CMAJ Open | View What constitutes the most cautious approach for a pregnant person with weak D type 4.0? | Health care providers | Benchmarking and standard setting |
Recognizing Vaccine-Induced Immune Thrombotic Thrombocytopenia | Iba T, Levy JH, Warkentin TE | 2022 | Crit Care Med | View Recognizing Vaccine-Induced Immune Thrombotic Thrombocytopenia | Health care providers | Benchmarking and standard setting |
Systematic Scoping Review of Studies Reporting Unexpected Donor-Derived Abnormalities from Recipients of Allogeneic Hematopoietic Cell Transplantation: A Proposed Framework for Donor Disclosure | Candeliere J, Kirkham AM, Shorr R, Morris G, Berardi P, Seftel MD, Allan DS | 2022 | Cell Ther Transplant | View Systematic Scoping Review of Studies Reporting Unexpected Donor-Derived Abnormalities from Recipients of Allogeneic Hematopoietic Cell Transplantation: A Proposed Framework for Donor Disclosure | Health care providers | New or improved product or process |
Le dépistage bactériologique des plaquettes à la Société canadienne du sang | Khandelwal A, Ramirez-Arcos S, Bigham M | 2022 | Blood.ca website | View Le dépistage bactériologique des plaquettes à la Société canadienne du sang | Health care providers | Benchmarking and standard setting |
FAQ : plasma traité au solvant-détergent (Octaplasma) | Mack J, Gordon I, Romans R, Webert K, Ning S, Zeller M | 2023 | Blood.ca website | View FAQ : plasma traité au solvant-détergent (Octaplasma) | Health care providers | New or improved product or process |